


Please add the following new claims:

--15. (New) A 8-azabicyclo[3.2.1]oct-2-ene compound of Formula II,



wherein

R is hydrogen, methyl, ethyl or benzyl; and

R¹ is 3-thienyl, 2-thienyl, 2-(3-methoxymethyl), 3-quinolinyl, 3-benzofuryl, 2-benzofuryl, 3-benzothienyl, 2-benzothienyl, 2-benzothiazolyl, 2-thieno[3.2-b]thienyl, thiено[2.3-b]thienyl, 2-(3-bromo)benzofuryl or 2-(3-bromo)benzothienyl.--

--16. (New) The 8-azabicyclo[3.2.1]oct-2-ene compound of claim 15 which is

(±)-8-Methyl-3-(3-quinolinyl)-8-azabicyclo[3.2.1]oct-2-ene;

(±)-3-(3-Benzofuryl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;

(±)-3-(3-Benzothienyl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;

(±)-3-(2-Benzofuryl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;

(±)-3-(2-Benzothienyl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;

(±)-3-(2-Benzothiazolyl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;

(±)-3-(2-Thieno[3.2-b]thienyl)-8-methyl-8-azabicyclo[3.2.1]oct-

2-ene;

(\pm) -3- (2-Thieno[2.3-b]thienyl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene;

(\pm) -3- (2-Benzofuryl)-8-H-8-azabicyclo[3.2.1]oct-2-ene;

(\pm) -3- (2-Benzofuryl)-8-ethyl-8-azabicyclo[3.2.1]oct-2-ene;


(\pm) -3- [2- (3-Bromobenzofuryl)]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene; or

(\pm) -3- [2- (3-Bromobenzothienyl)]-8-methyl-8-azabicyclo[3.2.1]oct-2-ene; or a pharmaceutically acceptable addition salt thereof.--

--17. (New) A pharmaceutical composition, comprising a therapeutically effective amount of a 8-azabicyclo[3.2.1]oct-2-ene compound of claim 15, or a pharmaceutically acceptable addition salt thereof, together with at least one pharmaceutically acceptable carrier or diluent.--

--18. (New) A method for the preparation of the 8-azabicyclo[3.2.1]oct-2-ene compound of claim 15, comprising

a) the step of reacting a compound having the formula




wherein R is as defined in claim 15,
with a compound of formula R¹-X,

wherein R¹ is as defined in claim 15,

and X is halogen, boronic acid, or trialkylstanny; or

b) the step of reducing a compound having the formula



wherein R¹ is as defined in claim 15.--

--19. (New) A method of treating a disease of a living animal body, including a human, which disease is responsive to the activity of nicotinic ACh receptor modulators, comprising the step of administering to such a living animal body, including a human, in need thereof a therapeutically effective amount of a compound according to claim 15.--

--20. (New) The method according to claim 19, wherein pain, a disease in the central nervous system, a disease caused by smooth muscle contraction, neurodegeneration, inflammation, chemical substance abuse or withdrawal symptoms caused by the cessation of intake of the chemical substance are treated.--

--21. (New) The method according to claim 20, wherein chemical substance abuse or withdrawal symptoms caused by the cessation of intake of the chemical substance, said chemical substance abuse being smoking or use of

other nicotine containing products and withdrawal symptoms caused by cessation of use of nicotine containing products, is treated.--

--22. (New) The method of claim 21, wherein a disease in the central nervous system, said disease being Alzheimer's disease, Parkinson's disease, memory dysfunction or attention deficit hyperactivity disorder, is treated.--

--23. (New) The method of claim 22, wherein depression is treated.--